Overall, STAT3 inhibition reversed the unfavorable effects of LDHC silencing in HCC-1954 cells and reduced the cancer cell survival of siCTRL cells, indicating that HCC-1954 cells do not benefit from LDHC-targeted therapy but may benefit from monotherapy with STAT3 inhibitors. This evidence concerns the gene STAT3 and cancer.